General Information of Drug Combination (ID: DCLFAOP)

Drug Combination Name
Taxol MK-5108
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs Taxol   DMUOT9V MK-5108   DMFGYKS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: MDAMB436
Zero Interaction Potency (ZIP) Score: 6.52
Bliss Independence Score: 6.24
Loewe Additivity Score: 3.35
LHighest Single Agent (HSA) Score: 7.63

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Pancreatic cancer 2C10 Phase 3 [4]
Gastric adenocarcinoma 2B72 Phase 2 [5]
Ovarian cancer 2C73 Phase 2 [5]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [2]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of MK-5108
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
MK-5108 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aurora kinase B (AURKB) TT5LS6T AURKB_HUMAN Inhibitor [7]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCBWEPY ES2 Investigative [8]
Breast and ovarian cancer syndrome DCY402E UWB1289 Investigative [1]
Breast and ovarian cancer syndrome DC7Z562 UWB1289+BRCA1 Investigative [1]
Breast carcinoma DCU9KRX OCUBM Investigative [1]
Carcinoma DCNS58T EFM192B Investigative [1]
Colon adenocarcinoma DCNN52G LOVO Investigative [1]
Invasive ductal carcinoma DCEJTCT T-47D Investigative [1]
Adenocarcinoma DC6EEQ1 CAOV3 Investigative [9]
Adenocarcinoma DC0U3B1 A427 Investigative [9]
Adenocarcinoma DCWJK29 NCIH1650 Investigative [9]
Adenocarcinoma DC8X8MF NCIH2122 Investigative [9]
Adenocarcinoma DCAY37I NCIH23 Investigative [9]
Adenocarcinoma DCLWNDA NCIH520 Investigative [9]
Adenocarcinoma DCXOZI7 COLO320DM Investigative [9]
Adenocarcinoma DCCX2OC DLD1 Investigative [9]
Adenocarcinoma DCAZ0ZG SW-620 Investigative [9]
Amelanotic melanoma DCF7PIV A2058 Investigative [9]
Germ cell tumour DC6AI7I PA1 Investigative [9]
Large cell lung carcinoma DC6KJ76 NCI-H460 Investigative [9]
Malignant melanoma DCW9M6D RPMI7951 Investigative [9]
Malignant melanoma DCD8CR0 SKMEL30 Investigative [9]
Mesothelioma DC59QWU MSTO Investigative [9]
Non small cell carcinoma DC4ZLGG SKMES1 Investigative [9]
Ovarian endometrioid adenocarcinoma DCU846O A2780 Investigative [9]
Prostate carcinoma DCG0S7C VCAP Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
7 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
8 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.